61

Stryker Corp. (SYK-N)

ON STOCKCHASE SINCE Feb 2002

manufactures orthopedic equipment

biotechnology/pharmaceutical

Stryker Corp.
SYK-N

29 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about SYK-N

Signal	Opinion	Expert
HOLD	Stryker Corp.(SYK-N) February 15, 2019 Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $187.400 Owned Unknown

BUY	Stryker Corp.(SYK-N) February 13, 2019 A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Harris, CF Portfolio , Avenue Investment Ma... Price $185.630 Owned Unknown
BUY	Stryker Corp.(SYK-N) February 6, 2019 They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $180.700 Owned No
TOP PICK	Stryker Corp.(SYK-N) February 4, 2019 Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40) biotechnology/pharmaceutical 0 0 0 0 0 0 comments John O'Connell, Chairman a, Davis Rea... Price $176.290 Owned Yes
TOP PICK	Stryker Corp.(SYK-N) November 20, 2018 His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Zachary Curry Chief Oper, Davis-Rea Ltd.... Price $165.950 Owned Yes
PAST TOP PICK	Stryker Corp.(SYK-N) October 12, 2018 (A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $171.040 Owned Yes
HOLD	Stryker Corp.(SYK-N) September 12, 2018 This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N biotechnology/pharmaceutical 0 0 0 0 0 0 comments	This is a great company, he says, with a well-established track record. The price is getting to the point, where you are paying a premium at this level. He would diversify into other holdings as well, ideally through an ETF such as IHI-N biotechnology/pharmaceutical 0 0 0 0 0 0 comments Cameron Hurst Chief Inve, Equium Capital Manag... Price $173.290 Owned No
COMMENT	Stryker Corp.(SYK-N) August 7, 2018 They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Cameron Hurst Chief Inve, Equium Capital Manag... Price $165.180 Owned No
TOP PICK	Stryker Corp.(SYK-N) August 7, 2018 Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10) biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Driscoll President , Liberty Internationa... Price $165.180 Owned Yes
BUY	Stryker Corp.(SYK-N) July 5, 2018 They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $171.330 Owned Yes
BUY	Stryker Corp.(SYK-N) June 20, 2018 He has been watching them since $100. They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices. There is a rumour they may look to make a major acquisition. For a 5-10 year horizon, this is a great core holding. Yield %. (Analysts’ price target is unkown) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He has been watching them since $100. They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices. There is a rumour they may look to make a major acquisition. For a 5-10 year horizon, this is a great core holding. Yield %. (Analysts’ price target is unkown) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Jason Del Vicar Portfolio , HollisWealth... Price $169.540 Owned No
BUY	Stryker Corp.(SYK-N) June 12, 2018 This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15. biotechnology/pharmaceutical 0 0 0 0 0 0 comments David Baskin President, Baskin Wealth Manage... Price $162.540 Owned No
TOP PICK	Stryker Corp.(SYK-N) March 21, 2018 Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $164.730 Owned Yes
BUY	Stryker Corp.(SYK-N) March 21, 2018 Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Macdonald Chief Inve, Harvest Portfolios G... Price $164.730 Owned Yes
PAST TOP PICK	Stryker Corp.(SYK-N) February 14, 2018 (A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Zachary Curry Chief Oper, Davis-Rea Ltd.... Price $156.240 Owned Yes

7+

JOIN THE DISCUSSION
7 comments in the last 7 days

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.